Lucid Capital analyst Elemer Piros initiated coverage of Unicycive Therapeutics (UNCY) with a Buy rating and $12 price target The company could launch oxylanthanum carbonate in the second half of 2025, one of the first innovative products in over a decade for the treatment of hyperphosphatemia, the analyst tells investors in a research note. The firm says Unicycive is building a “comprehensive” drug portfolio for chronic kidney disease and acute kidney injury.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNCY:
- Buy Rating for Unicycive Therapeutics: Innovative Approach to Hyperphosphatemia Treatment with Oxylanthanum Carbonate
- Unicycive Therapeutics assumed with a Buy at H.C. Wainwright
- Unicycive Therapeutics Updates Annual Meeting Time
- Unicycive Therapeutics announces time change for FY25 annual meeting
- Buy Rating for Unicycive Therapeutics Driven by Strategic Positioning and Upcoming Regulatory Milestones